Ardelyx has given long term holders a very different ride from what the recent slump suggests, with a strong multi year return sitting beside a sharp pullback this year. That mix of outcomes puts the spotlight on one thing for anyone looking at the stock today: whether the current share price is adequately backed by the company’s sales. Over the past 5 years, Ardelyx has delivered a 156.8% gain, which makes the current drawdown more important for judging how much of that share price move its...
Ardelyx (ARDX) just paired fresh third quarter 2026 results with progress in its IBSRELA pipeline, giving investors new numbers on current operations alongside an update on its late stage ACCEL trial. That progress has arrived against a tougher tape for Ardelyx, with the share price down 38.3% over the past 90 days and year to date off 50.7%, even though the 5 year total shareholder return is still positive at 156.8%. This shows that long term holders have seen gains, while recent momentum...
Motley Fool Press Release.
Doubling the field reimbursement team targets prior authorization friction, a hurdle that can stall prescriptions even after demand is established.
Ardelyx Inc (ARDX) posted $125.5 million in Q3 2026 product revenue on 23% IBSRELA growth, narrowed its net loss to $700,000, and reaffirmed full-year guidance while targeting profitability in 2027.
Ardelyx (NASDAQ:ARDX) reported third-quarter product revenue of $125.5 million, up 19% from the prior-year period, as growth in its IBS-C treatment IBSRELA offset more modest revenue growth for dialysis-focused drug XPHOZAH. President and Chief Executive Officer Mike Raab said the company’s two fir
Tipranks Press Release.
NewMediaWire Press Release.
Newsfile Press Release.
NewMediaWire Press Release.
Recognition includes Life Sciences Manufacturer CEO of the Year, Podcast Initiative, and Marketing Team of the YearWALTHAM, Mass., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced that it received multiple honors at the 2026 PM360 Trailblazer Awards, recognizing the company, its leadership, and the work of
Detailed price information for Ardelyx Inc (ARDX-Q) from The Globe and Mail including charting and trades.
This is the newest page. Registered accounts read further back.